Advanced search
1 file | 131.04 KB

Selecting neonates with congenital cytomegalovirus infection for ganciclovir therapy

(2006) EUROPEAN JOURNAL OF PEDIATRICS. 165(12). p.885-890
Author
Organization
Abstract
Objective: The objective of this study is to look for evidence based or scientific guidelines for selection of newborns with congenital cytomegalovirus (CMV) infection that might benefit from treatment with ganciclovir. Materials and methods: A literature search was conducted involving the MEDLINE database and the Cochrane Collaboration Library. Abstracts were reviewed to select pertinent articles dealing with ganciclovir therapy in neonates. References from selected articles as well as from reviews were screened for additional relevant articles. In total, 13 case reports (16 patients in all), three descriptive uncontrolled studies (20 patients in all), two randomized dose-comparative studies (54 patients in all) and one randomized controlled study (42 patients) were identified. Observations: All reported patients presented with central nervous system manifestation of CMV infection. Only the randomized controlled study showed a reduction of hearing deterioration in the treated group. Published predictors of hearing loss in congenitally CMV infected children allow identification of candidates that might benefit from treatment. Studies so far are promising but of insufficient number to make evidence based recommendations about indications for treatment of congenital CMV. As such, studies are very difficult to conduct and treatment of infants at high risk of hearing loss may appear justified. There is scientific data to help clinicians in selecting a subgroup of infants that is at higher risk of hearing deterioration and therefore might benefit the most from ganciclovir therapy.
Keywords
congenital cytomegalovirus infection, ganciclovir, treatment, sensorineural hearing loss, SENSORINEURAL HEARING-LOSS, CENTRAL-NERVOUS-SYSTEM, CHILDREN, INFANTS, DISEASE, VALGANCICLOVIR, PREDICTORS, NEWBORNS, RISK

Downloads

    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 131.04 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Smets, Koenraad, Kris De Coen, Ingeborg Dhooge, Lieve Standaert, Sabrina Laroche, Ludo Mahieu, Noël Logghe, Veerle Cossey, and An Boudewyns. 2006. “Selecting Neonates with Congenital Cytomegalovirus Infection for Ganciclovir Therapy.” European Journal of Pediatrics 165 (12): 885–890.
APA
Smets, Koenraad, De Coen, K., Dhooge, I., Standaert, L., Laroche, S., Mahieu, L., Logghe, N., et al. (2006). Selecting neonates with congenital cytomegalovirus infection for ganciclovir therapy. EUROPEAN JOURNAL OF PEDIATRICS, 165(12), 885–890.
Vancouver
1.
Smets K, De Coen K, Dhooge I, Standaert L, Laroche S, Mahieu L, et al. Selecting neonates with congenital cytomegalovirus infection for ganciclovir therapy. EUROPEAN JOURNAL OF PEDIATRICS. 2006;165(12):885–90.
MLA
Smets, Koenraad, Kris De Coen, Ingeborg Dhooge, et al. “Selecting Neonates with Congenital Cytomegalovirus Infection for Ganciclovir Therapy.” EUROPEAN JOURNAL OF PEDIATRICS 165.12 (2006): 885–890. Print.
@article{364550,
  abstract     = {Objective: The objective of this study is to look for evidence based or scientific guidelines for selection of newborns with congenital cytomegalovirus (CMV) infection that might benefit from treatment with ganciclovir. 
Materials and methods: A literature search was conducted involving the MEDLINE database and the Cochrane Collaboration Library. Abstracts were reviewed to select pertinent articles dealing with ganciclovir therapy in neonates. References from selected articles as well as from reviews were screened for additional relevant articles. In total, 13 case reports (16 patients in all), three descriptive uncontrolled studies (20 patients in all), two randomized dose-comparative studies (54 patients in all) and one randomized controlled study (42 patients) were identified. 
Observations: All reported patients presented with central nervous system manifestation of CMV infection. Only the randomized controlled study showed a reduction of hearing deterioration in the treated group. Published predictors of hearing loss in congenitally CMV infected children allow identification of candidates that might benefit from treatment. Studies so far are promising but of insufficient number to make evidence based recommendations about indications for treatment of congenital CMV. As such, studies are very difficult to conduct and treatment of infants at high risk of hearing loss may appear justified. There is scientific data to help clinicians in selecting a subgroup of infants that is at higher risk of hearing deterioration and therefore might benefit the most from ganciclovir therapy.},
  author       = {Smets, Koenraad and De Coen, Kris and Dhooge, Ingeborg and Standaert, Lieve and Laroche, Sabrina and Mahieu, Ludo and Logghe, No{\"e}l and Cossey, Veerle and Boudewyns, An},
  issn         = {0340-6199},
  journal      = {EUROPEAN JOURNAL OF PEDIATRICS},
  keyword      = {congenital cytomegalovirus infection,ganciclovir,treatment,sensorineural hearing loss,SENSORINEURAL HEARING-LOSS,CENTRAL-NERVOUS-SYSTEM,CHILDREN,INFANTS,DISEASE,VALGANCICLOVIR,PREDICTORS,NEWBORNS,RISK},
  language     = {eng},
  number       = {12},
  pages        = {885--890},
  title        = {Selecting neonates with congenital cytomegalovirus infection for ganciclovir therapy},
  url          = {http://dx.doi.org/10.1007/s00431-006-0192-2},
  volume       = {165},
  year         = {2006},
}

Altmetric
View in Altmetric
Web of Science
Times cited: